Checkmate Pharmaceuticals
treatment related adverse events were generally manageable checkmate | Checkmate Pharmaceuticals
Company
Deck Type
IPO
Deck date
August 2020
Slide
22 of 34
Related slides by other companies
Nuvalent
Investor Presentation
April 2024
preliminary safety profile favorable and consistent with the highly selective sparing design of phase treatment related adverse events in patient all treated patients no no treatment related no aes leading to dose reduction or discontinuation no treatment related fatigue alt increased ast increased myalgia grade grade any grade grade ses alt aint as aspartate source a doe serous ses i | Nuvalent
CG Oncology
IPO
March 2024
has been generally well tolerated with no grade or higher treatment related aes | CG Oncology
Dare Bioscience
Investor Presentation
July 2023
female adverse event rates similar between groups | Dare Bioscience
Nuvalent
Investor Presentation
January 2024
preliminary safety profile favorable and consistent with the highly selective sparing design of in no no treatment related no aes leading to dose eduction or or discontinuation ion no treatment related dizziness treatment related adverse events in patient all treated patients fatigue alt increased ast increased myalgia grade grade grade any grade data as for patients treated by adverse event alt alanine ast aspartate dose limiting toxicity including source a a | Nuvalent
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io